埃弗雷斯特医药公司计划筹集2亿美元,以促进AI+mRNA研究和产品推出. Everest Medicines plans to raise $200M to boost AI+mRNA research and product launches.

珠穆朗玛峰医药公司是一家总部设在香港的生物制药公司,计划通过股份安排筹集约1.57亿港元(2亿美元)。 Everest Medicines, a biopharmaceutical company based in Hong Kong, plans to raise around HK$1.57 billion (US$200 million) through a share placement. 这些资金将主要用于研究和开发(50%)、商业化工作(40%)和周转资金(10%)。 The funds will be mainly used for research and development (50%), commercialization efforts (40%), and working capital (10%). 这一安排得到国际资金的大力支持,将有助于加速开发其AI+mRNA平台和推出新产品。 The placement, well-supported by international funds, will help accelerate the development of its AI+mRNA platform and the launch of new products.